Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

Inclusion Criteria:

• Males or females, aged >= 18 years at time of consent.

• Have a diagnosis of Psoriatic arthritis (PsA) of >= 6 months

• Meet the Classification Criteria of PsA (CASPAR) at time of screening

• Must not have been adequately treated with a a traditional non-biologic diseasemodifying anti-rheumatic drug (DMARD).

• Concurrent treatment with methotrexate, leflunomide, or sulfasalazine allowed andrequired

• Must not have taken a biologic Tumour Necrosis Factor Inhibitor

• Must have 3 or more swollen joints AND 3 or more tender joints

• Must have active psoriasis skin lesions

Exclusion Criteria:

• Have non-plaque forms of psoriasis, eg erythrodermic, guttate or pustular, with theexception of nail psoriasis which is allowed

• Pregnant or breast feeding, females of child-bearing potential not using highlyeffective contraception

• New York Heart Association Class III and IV congestive heart failure

• History of hypersensitivity or infusion reaction to biologic agents

• Infection with HIV, hepatitis B virus, hepatitis C virus, or other chronic infection